CAMBRIDGE, Mass., Feb 24, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the 2011 RBC Capital Markets' Healthcare Conference being
held at the New York Palace Hotel in New York City. Harvey J. Berger,
M.D., chairman and chief executive officer at ARIAD, will provide an
overview of the Company's strong oncology pipeline and progress on its
three lead compounds on Thursday, March 3, at 8:30 a.m. (ET). Dr. Berger
will host 1-on-1 meetings with investors following the Company's
presentation.
The ARIAD presentation will be webcast live and can be accessed by
visiting the investor relations section of the Company's website at http://www.ariad.com/investor.
A replay of the presentation will be available on the ARIAD website
approximately one hour after the presentation and will be archived for
two weeks.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with
breakthrough medicines. The Company's mission is to discover, develop
and commercialize small-molecule drugs to treat cancer in patients with
the greatest and most urgent unmet medical need - aggressive cancers
where current therapies are inadequate. ARIAD's lead product candidate,
ridaforolimus, is an investigational mTOR inhibitor being developed by
Merck that has successfully completed a Phase 3 clinical trial in
patients with soft-tissue and bone sarcomas and is being studied in
multiple cancer indications. ARIAD's second internally discovered
product candidate, ponatinib, is an investigational pan-BCR-ABL
inhibitor in a pivotal Phase 2 clinical trial in patients with chronic
myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional
information, please visit www.ariad.com.
SOURCE: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208
